Creatine Monohydrate
Creatine Monohydrate is classified under Group A (Evidence-Supported Sports Nutrition & Ergogenic Aids). While specific physiological and performance benefits are supported in peer-reviewed sports nutrition literature, dietary supplements are not universally safe, cannot replace whole-food nutrition, and carry real risks of undeclared prohibited-substance contamination (10–25% of uncertified commercial supplements). Always consult a qualified physician, pharmacist, or accredited sports dietitian.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Creatine Monohydrate
Common Names, Synonyms & Classifications: N-(Aminoiminomethyl)-N-methylglycine monohydrate; Micronised Creatine Monohydrate; Phosphocreatine Precursor
Section Classification: Group A — Evidence-Supported Sports Nutrition & Ergogenic Aids (PERF-A01)
2. Pharmacological Class
Guanidino-Compound Ergogenic Aid & Cellular ATP-Phosphagen Buffer
3. Mechanism of Action
Increases intramuscular total creatine and phosphocreatine (PCr) stores by 15–40%. During maximal high-intensity exercise, creatine kinase (CK) catalyses reversible phosphoryl transfer from PCr to ADP to rapidly resynthesise ATP (PCr + ADP + H⁺ ↔ ATP + Creatine), buffering intracellular hydrogen ions and accelerating PCr resynthesis between repeated sprint/resistance bouts.
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological Effect: Elevates skeletal muscle phosphocreatine pool and intracellular water retention. Proven Athletic Performance Benefit: Consistently improves peak power output, single- and repeated-sprint work capacity (bouts lasting <30 seconds), and lean body mass adaptations during resistance training. Unsupported Claims: Does not directly improve steady-state submaximal aerobic marathon time when no high-intensity surges are involved.
5. Quality of Scientific Evidence
Evidence Assessment: High / Level A Consensus (IOC Consensus Statement & ISSN Position Stand — Strongest evidence base among non-prohibited ergogenic aids)
6. Approved Medical Uses (Where Applicable)
Investigational/adjunctive nutritional support in inborn errors of creatine synthesis (GAMT/AGAT deficiency), certain muscular dystrophies, and age-related sarcopenia; primarily regulated as a sports nutrition supplement.
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
Evidence-based maintenance intake is 3–5 g/day of pure Creatine Monohydrate. Misuse patterns include excessive megadosing (>20–30 g/day chronically), relying on unverified novel esters ('creatine ethyl ester' or liquid creatine, which degrade rapidly to inactive creatinine in gastric acid), or purchasing uncertified blends contaminated with prohibited anabolic agents.
8. Adverse Effects & Serious Safety Risks
Intracellular osmotic water retention (1–2 kg body mass increase), transient gastrointestinal cramping or osmotic diarrhoea if large single doses (>10 g) are ingested incompletely dissolved. Elevates benign serum creatinine (a metabolic byproduct of muscle creatine turnover) which can falsely lower calculated Cockcroft-Gault/eGFR estimates without true tubular kidney injury in healthy individuals.
9. Contraindications & Precautions
Pre-existing chronic kidney disease (CKD Stages 3–5), acute kidney injury, nephrotic syndrome, or uncorrected dehydration. In weight-category sports (wrestling, boxing, weightlifting), intracellular water weight gain requires dietary planning.
10. Drug Interactions
Concurrent nephrotoxic drugs (NSAIDs, aminoglycosides, cyclosporine) require renal monitoring. High-dose chronic caffeine or ephedra co-ingestion was historically debated; combine only with adequate fluid intake.
11. Clinical & Laboratory Monitoring Considerations
Baseline and periodic serum cystatin C (preferred over serum creatinine alone in muscular athletes) and urinalysis if underlying renal risk factors exist; verify third-party batch testing certificate (Informed-Sport / NSF Certified for Sport).
12. Dependence, Misuse or Withdrawal Concerns
No physiological dependence, addiction, or neurochemical withdrawal syndrome. Intramuscular phosphocreatine stores return gradually to baseline over 4–6 weeks after cessation.
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
Regulated in India as a Food for Special Dietary Uses (FSDU) / Sports Supplement under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2022 (FSSAI). Not a CDSCO prescription schedule drug.
14. Official WADA Prohibited-List Status
NOT PROHIBITED (Permitted in-competition and out-of-competition under the WADA Prohibited List, provided the product is free of undeclared prohibited contaminants).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026